Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...
Natural killer cells, or NK cells, are elements of the immune system capable of rapidly locating and destroying cancerous or ...
A new method for engineering natural killer cells could make cancer immunotherapy more efficient, scalable, and affordable, ...